Doctor of Dentistry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Matthews

Dentist, Orofacial Pain Stone Mountain, GA Doctor of Dentistry

NPI 1710984695 CMS profile 123622

2415 W Park Place Blvd, Stone Mountain, GA 30087

Open in the dashboard

General payments

$2,301

83 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Matthews of Stone Mountain, GA is reported in the CMS Open Payments database as having received $2,301 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Dentist, Orofacial Pain profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $290 1
2024 General $14 1
2023 General $30 1
2022 General $436 18
2021 General $482 16
2020 General $488 24
2019 General $561 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Matthews
  • Dentist, Orofacial Pain median
  • Middle half of Dentist, Orofacial Pain
  • National median

In program year 2025, general payments to Joseph Matthews were reported at $290. Among 51 Dentist, Orofacial Pain profiles paid that year, the median was $95 and the middle half received between $23 and $171.

Show as a table
Year Joseph Matthews Dentist, Orofacial Pain median Middle half National median
2019 $561 $102 $46–$213 $163
2020 $488 $62 $16–$136 $114
2021 $482 $120 $32–$293 $132
2022 $436 $161 $70–$404 $149
2023 $30 $76 $28–$200 $160
2024 $14 $71 $26–$196 $164
2025 $290 $95 $23–$171 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $505 28 payments
  2. Novartis Pharmaceuticals Corporation $312 11 payments
  3. Biohaven Pharmaceuticals, Inc. $293 6 payments
  4. Ultradent Products Inc $290 1 payment
  5. Amgen Inc. $242 11 payments
  6. AbbVie, Inc. $177 2 payments
  7. Lilly USA, LLC $134 9 payments
  8. Allergan Inc. $124 2 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $79 5 payments
  10. Merz Pharmaceuticals, LLC $44 2 payments
  11. Other $100 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,010 82 payments
  2. Gift $290 1 payment
Products named General payments · program years 2019–2025
  1. AIMOVIG $555 22 payments
  2. NURTEC ODT $372 11 payments
  3. Opalescence $290 1 payment
  4. AJOVY Central Nervous System $284 17 payments
  5. EMGALITY $134 9 payments
  6. BOTOX COSMETIC $124 2 payments
  7. Ajovy Central Nervous System $117 10 payments
  8. AUSTEDO $104 1 payment
  9. QULIPTA $75 1 payment
  10. HETLIOZ $36 2 payments
  11. Other $220 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dentist, Orofacial Pain in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record